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Background: Decreased lean body mass (LBM) is common in breast cancer survivors yet currently there is a lack of
information regarding the determinants of LBM after treatment, in particular, the effect of physical activity and
dietary factors, such as long-chain omega-3 fatty acids (LCn-3) on LBM and LBM function. This cross-sectional study
explored associations of LBM and function with LCn-3 intake, dietary intake, inflammation, quality of life (QOL) and
physical fitness in breast cancer survivors to improve clinical considerations when addressing body composition
change.
Methods: Forty-nine women who had completed treatment (surgery, radiation and/or chemotherapy) were assessed
for body composition (BODPOD), LCn-3 content of erythrocytes, C-reactive protein (CRP), QOL, dietary intake, objective
physical activity, 1-min push-ups, 1-min sit-stand, sub-maximal treadmill (TM) test, and handgrip strength.
Results: After adjustment for age, LBM was associated with push-ups (r = 0.343, p = 0.000), stage reached on treadmill
(StageTM) (r = 0.302, 0.001), % time spent ≥moderate activity (Mod + Vig) (r = 0.228, p = 0.024). No associations were
seen between anthropometric values and any treatment, diagnostic and demographical variables. Body mass,
push-ups and StageTM accounted for 76.4% of the variability in LBM (adjusted r-square: 0.764, p = 0.000). After
adjustment docosahexanoic acid (DHA) was positively associated with push-ups (β=0.399, p = 0.001), eicosapentanoic
acid (EPA) was negatively associated with squats (r = −0.268, p = 0.041), with no other significant interactions found
between LCn-3 and physical activity for LBM or LBM function.
Conclusion: This is the first investigation to report that a higher weight adjusted LBM is associated with higher
estimated aerobic fitness and ability to perform push-ups in breast cancer survivors. Potential LCn-3 and physical
activity interactions on LBM require further exploration.
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Loss of lean body mass (LBM) and simultaneous gains
in fat mass are amongst the most common side effects
following treatment for breast cancer (Mcdonald et al.
2011). This pattern of body composition change is dis-
tressing for the survivors and it is related to higher levels
of chronic inflammation (Mourtzakis & Bedbrook 2009),
and a greater risk for metabolic syndrome (Healy et al.
2010) and its related diseases (Healy et al. 2010; Pierce
et al. 2009). A growing literature has established LBM,* Correspondence: c.mcdonald4@uq.edu.au
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in any medium, provided the original work is pand in particular skeletal muscle tissue, as an influential
organ in hormonal, immune and metabolic function
(Pedersen & Febbraio 2012). Lifestyle factors such as
physical activity and nutrient intake can enhance LBM
size (Irwin et al. 2009) and function, (Courneya et al.
2007; Schmitz et al. 2005) and have also been associated
with improved survival (Ibrahim & Al-Homaidh 2010)
and quality of life (Mcneely et al. 2006) after treatment
for breast cancer. Taken together, LBM is becoming an
important marker for women who have been diagnosed
with breast cancer.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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that chemotherapy has been associated with declines of
LBM during and after treatment (Cheney et al. 1994;
Demark-Wahnefried et al. 1997; Demark-Wahnefried
et al. 2001; Gordon et al. 2011; Kutynec et al. 1999),
however not all trials have reported LBM loss after
chemotherapy (Campbell et al. 2007). In contrast, associ-
ations between higher LBM and aromatase inhibitor
hormonal therapy have been reported in three different
data sets (Francini et al. 2006; Montagnani et al. 2008;
Van Londen et al. 2011). Modifiable variables such as
dietary intake and physical activity have not been exten-
sively explored with regard to LBM change in breast
cancer populations. Some evidence exists for an associ-
ation between decreased physical activity and increased
adiposity (Irwin et al. 2005), while mixed results have
been reported in relation to dietary intake and adiposity,
(Sheean et al. 2012) however a deeper understanding of
physical activity, dietary factors and LBM change are
needed to better guide clinicians in the post-treatment
period.
Long chain omega-3 fatty acids (LCn-3) are estab-
lished as anti-inflammatory agents and have been shown
to protect LBM in cancer populations (Dewey et al.
2001; Murphy et al. 2012; Ries et al. 2012; Van Der Meij
et al. 2011). However, conclusions from reviews of inter-
vention studies in cancer populations investigating the
effect of LCn-3’s on LBM have been mixed (Murphy
et al. 2012; Ries et al. 2012). Typically, older studies have
shown a protective effect for LBM when the appropriate
dose of LCn-3 is consumed (Fearon et al. 2006; Fearon
et al. 2003). More recent studies investigating 2 g of EPA
LCn-3 supplementation in individuals undergoing chemo-
therapy for non-small cell lung cancer (NSCLC) have
shown significantly greater attenuation of LBM and im-
proved levels of intra-muscular triglyceride (IMTG), com-
pared to those not supplementing. (Murphy et al. 2010;
Murphy et al. 2011). In non-cancer populations the ef-
fect of LCn-3 on LBM has been minimal, with the ma-
jority of controlled trials indicating limited clinical
effect (Mcdonald et al. 2013b).
Recent research has indicated that a greater effect may
be seen when LCn-3 s are combined with an anabolic
stimulus (Mcdonald et al. 2013b; Rodacki et al. 2012;
Smith et al. 2011a; Smith et al. 2011b). Three small, well
controlled studies combined LCn-3 supplementation
with exposure to an anabolic stimulus, i.e. hyperinsuli-
naemic/hyperaminoacidaemic clamp or resistance train-
ing. Two reported an increased muscle protein synthetic
(MPS) response to for young healthy (Smith et al.
2011b), and elderly participants (Smith et al. 2011a), yet
LCn-3 alone made no difference to basal MPS. The third
study that used resistance training reported increased
peak torque development for the supplemented groupabove that of the group who received the resistance
training program only (Rodacki et al. 2012). Considering
LBM function, measured by strength or power develop-
ment, may be more important to health outcomes than
absolute values of LBM, (Newman et al. 2006; Ruiz et al.
2008) further investigations are required.
Therefore, the objectives of this cross-sectional study
was to explore associations of LBM and LBM function
in the context of LCn-3 intake, dietary energy and pro-
tein intake, inflammation, quality of life (QOL) and pa-
rameters of physical fitness and activity in women who
had completed breast cancer treatment. A secondary
goal was to determine the effect of interactions between
tissue content of LCn-3 and markers of physical fitness
on LBM after treatment for breast cancer.
Methods
Study design
All participants provided written informed consent. The
data presented here was collected as the baseline assess-
ment for a 6-month 3-arm randomized controlled trial
(RCT) investigating LBM in women who have com-
pleted treatment for breast cancer. Detailed rationale
study protocol for the full trial has been published previ-
ously (Mcdonald et al. 2013a). The study was approved by
the Uniting Care (UCH HREC: #1034) and the University
of Queensland (#2011000079).
Participants
Participants were invited to participate through hospital
breast cancer oncology centres, radio advertising, social
media and breast cancer research registries in Brisbane,
Australia. Baseline assessment occurred over one week,
which included two visits 7 days apart.
Eligibility
Women ≥18 years of age; had been diagnosed with early
stage breast cancer (Stage 0-IIIa as determined by the
American Joint Committee on Cancer Care); had suc-
cessfully completed surgery, radiation and/or chemo-
therapy in the last 12 months (participants could be
currently receiving endocrine and/or herceptin therapy);
were able to perform moderate intensity physical activity,
and have a BMI of >20 and <35 kg/m2 were eligible for
enrolment. Participants were excluded if they had pres-
ence of metastatic growth or local/distal recurrence of
cancer; a diagnosis of cardiovascular disease or diabetes;
or, consumed >1 g of eicosapentanoic acid (EPA) and doc-
osahexanoic acid (DHA) LCn-3 s combined per day.
Measures
Anthropometric variables
Height was measured to the nearest 0.5 cm using a sta-
diometer (Seca). Weight to the nearest 0.1 kg, LBM and
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scales and air displacement plethysmography (ADP) pod
(BODPOD, COSMED USA Inc), respectively. Before
each assessment day, the BODPOD scales and air cham-
ber were calibrated as per the manufacturer’s instructions
using known weights and volumes. All measures were per-
formed by a certified BODPOD assessor. Results were
expressed as percentage LBM and body fat of total weight,
then absolute LBM was calculated giving a value in kilo-
grams of LBM.
Quality of Life (QOL)
QOL was measured using the Functional Assessment of
Cancer Therapy- Breast + 4 (FACT-B + 4) tool (Cella et al.
1993). That FACT-F subset of questions was also added to
capture participant fatigue. Higher scores are representa-
tive of better well-being.
Diet history
Dietary intake was measured by the practitioner assisted
Diet History Questionnaire (Martin 2004). Participants
were asked to complete the questionnaire based on their
intake over the last month. An accredited practicing
dietitian reviewed the questionnaire with the participant
to clarify portion sizes and other relevant details. Nutri-
ent analysis was carried out using Foodworks 7 (Xyris
Software).
Blood analyses
Fasting high sensitivity-C Reactive Protein (CRP) was
measured using a latex-enhanced immunoturbidimetric
assay of blood serum. The 8.5 ml sample of whole blood
was collected and analysed for CRP, then frozen at −20°C
for transport to Victoria, Australia for fatty acid testing.
Lipids from red cells were extracted with chloroform
methanol mixture. The fatty acids were trans-esterificated
to methyl esters with methylation reagent “Meth-Prep 2”.
The methylation extract was then analysed by gas liquid
chromatography method with flame ionisation detection
(gas chromatograph Schimadzu G-2010-FID). The pro-
portion of fatty acids content of the erythrocytes expressed
as % of total fatty acids.
Muscle function and fitness tests
Grip strength was performed on both arms, with the
maximum of 3 attempts recorded. Participants were
seated with feet flat on floor, shoulder in neutral position
with elbow bent at 90 degrees. Upper body muscular
strength-endurance was measured using a 1-minute
push-up test. Participants were asked to perform as
many push-ups (knees on ground) as possible in 1 mi-
nute (American College of Sports Medicine 2010).
Lower body muscular endurance was measured using
a 1-minute sit-stand test. The participant was asked toperform as many sit-stand movements as possible in
1 minute. Chair height was standardised at 43 cm height
(American College of Sports Medicine 2010).
Sub-maximal aerobic capacity was measured using the
modified Balke sub-maximal treadmill test. Seated blood
pressure was measured before each assessment to ensure
safety of exercise (Sharman & Stowasserb 2009). The
test being completed when the individual had reached
85% of their estimated maximum heart rate (max HR)
(est. maxHR = 220-age).
Statistical analysis
Baseline characteristics were compared between treat-
ment types and stages of disease using independent sam-
ples t tests or ANOVA. Spearman’s correlation coefficient
was used assess the strength of bivariate associations, %
time in moderate and vigorous activity were grouped to-
gether into one variable: % time in ≥moderate activity. To
assess the significance of age- and/or weight-adjusted as-
sociations between an outcome and a potential predictor,
multivariable linear regression was used. Multivariable lin-
ear regression was used to model LBM as a function of
various markers of fitness while also controlling for total
body mass. For missing data, only those with full data sets
were included in the models. The variables considered for
inclusion in the model were those that were individually
associated with LBM after adjusting for age and weight.
Markers of fitness were added to the model sequentially,
with the order determined by decreasing r-values. A pre-
dictor was only retained in the model if its coefficient was
significantly different from zero at the 0.05 level. Adjusted
R-squared was used to compare nested models. Models
were also fitted that included interaction terms that ex-
plored the respective LCn-3 indices combined with fitness
markers on LBM.
Results
Participants were recruited over a 15-month period (Oct
2011 – Jan 2013). A total of 135 women were initially
screened for inclusion criteria. The major reasons for ex-
clusion were >12 months post treatment completion and
daily consumption of >1000 mg EPA and DHA com-
bined. Forty-nine participants were eligible for the study
and completed baseline assessment. Descriptive statistics
of the population are shown in Table 1.
Age
Age was positively correlated with improved breast can-
cer related QOL (r = 0.379, p = 0.007), fatigue (r = 0.311,
p = 0.30) and EPA (r = 0.339, p = 0.026), and negatively
correlated with % of time in vigorous activity (r = −0.342,
p = 0.022) and number of squats performed in 1-minute
(r = −0.363, p = 0.011).
Table 1 Characteristics of participants
Characteristic (n = 49) Value





—Asian Pacific Islander 1(2)
Anthropometric (mean; SD)
Height (m) 1.65 ± 0.07
BMI (kgm-2) 26.6 ± 4
Body mass (kg) 73.1 ± 13.8
LBM (kg) 43.6 ± 5.6
Body fat % 39.5 ± 6.9
Waist (cm) 85.4 ± 11.1
Hip Girth (cm) 106.3 ± 9.2
CRP (n = 45; med; range)* (0.1–10.1)
Total % RBC n-3 (n = 43)* 5.9 ± 1.6
% EPA 1.1 ± 0.5
% DHA 2.9 ± 0.9




Estrogen receptor + ve 39 (78)
HER-2 receptor + ve 12 (24)
Treatment variables (n; %)
Had Chemotherapy 41 (92)





Time since completion Rx 165 ± 107
AI–Aromatase inhibitors.
*Missing data.
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Compared to those diagnosed with earlier stage disease
(0-IIa), those with later stage disease (IIb-IIIa) re-
ported poorer results for BrCa related QOL (89.2 ±9.3
vs 79.3 ±15.7; p = 0.009), fatigue (130.5 ± 15.3 vs 113.3 ±
24.7; p = 0.006), total score for Greene climacteric scale
(11.8 ± 6.8 vs. 17.5 ± 10.2; F = 5.308, p = 0.026), with specif-
ically worse symptom scores reported for psychological,
anxiety, depression and somatic fields (all p < 0.05). Stage
of disease was not associated with any indices of body
composition, LCn-3 or physical function.Compared to those who did not have radiation ther-
apy, DHA values (t = 2.904; p = 0.016) and LCn-3: LCn-6
(t = 3.06; p = 0.004) ratios were higher for those who
underwent radiation therapy. Otherwise, radiation ther-
apy was not associated with markers of body compos-
ition, QOL, dietary intake, LBM function, endurance or
physical activity. Individuals taking tamoxifen tended to
have lower EPA content compared to those taking AIs
or no hormonal therapy (0.78% vs. 1.16% & 1.23%; F =
3.153, p = 0.054), however, there was no evidence to sup-
port an association between hormonal treatment and
other markers of body composition, QOL, dietary intake,
LBM function or physical activity.
Associations between LBM and dietary intake,
inflammation, physical activity, markers of fitness and
quality of life
LBM was positively correlated with daily intake of total
energy (r = 0.301, p = 0.036) and protein (r = 0.464, p =
0.001), and negatively correlated with higher squat test
results (r = −0.39, p = 0.006) (Table 2). However, after
adjusting for weight and age, the only significant associa-
tions with LBM were % time spent in ≥moderate inten-
sity activity (ß: 0.228, p = 0.024), number of push-ups
performed (ß: 0.343, p = 0.000) and treadmill stage com-
pleted (ß: 0.302, p = 0.001) (Table 2). CRP was positively
correlated with body fat %, waist and hip however, these
associations were no longer significant after controlling
for total body weight (data not shown).
Associations between LCn-3 and anthropometric indices,
inflammation & quality of life after breast cancer
treatment
No significant correlations were identified between abso-
lute LBM or % LBM for total RBC n-3, ratio of AA: EPA
or % RBC content of EPA or DHA (Table 3). No signifi-
cant relationships were found between any other an-
thropometric variables and n-3 related values.
No significant correlations were identified between
CRP and erythrocyte LCn-3. No markers of body com-
position, CRP or indices of LCn-3 intake were signifi-
cantly correlated with either measure of QOL.
Predictors of LBM in women soon after breast cancer
Number of push-ups, StageTM, and mod + vig activity
were considered for inclusion in a weight-adjusted linear
regression model for LBM (Table 2). Table 4 shows coef-
ficients for the variables included in the final model.
Table 4 also shows the value of adjusted R-squared ob-
tained as each variable was successively added to the
model. Mod + vig was not retained in the final model be-
cause the coefficient was not significantly different from
zero (β=0.115, p = 0.177) in the presence of the other
predictors. The model including weight, push ups and
Table 2 Associations between markers of absolute LBM and markers of LCn‐3 intake, dietary intake, physical activity
and fitness adjusted for weight & age n value
Lean body mass (kg) Body fat %
Unadjusted Adjusted Unadjusted Adjusted
R p-value Standardise d B-coefficient p-value R p-value Standardise d B-coefficient p-value
Total daily kJ intake 0.301 0.036 0.135 0.132 −0.82 0.576 −0.192 0.065
Total daily protein
intake 0.464 0.001 0.144 0.121 0.04 0.787 −0.197 0.068
CRP* 0.258 0.083 −0.128 0.238 0.597 0 0.123 0.343
% time in sedentary
activity* 0.167 0.273 0.053 0.579 0.23 0.88 −0.058 −0.524
% time in light activity* −0.149 0.329 −0.104 0.272 0.156 0.305 0.125 0.258
% time in >moderate
activity* −0.041 0.787 0.228 0.024 −0.466 0.001 −0.275 0.015
Push up (in 1-min)* −0.045 0.760 0.343 0.000 −0.671 0 −0.457 0
Squats (in 1-min)* −0.39 0.006 0.044 0.71 −0.454 0.001 −0.098 0.439
Stage of treadmill
completed −0.047 0.746 0.302 0.001 −0.575 0 −0.39 0
FACT-B + 4 −0.13 0.373 0.038 0.699 −0.146 0.316 −0.009 0.936
FACT-F −0.128 0.381 0.023 0.813 −0.133 0.362 −0.002 0.982
% time in activity: Accelerometry; % time in >moderate activity: moderate and vigorous activity grouped together; Stage of treadmill completed: at which 85% of
estimated HRmax was reached; *Reduced data: CRP: n = 46; Accelerometer data: n = 45; Push-ups: n = 48; Squats: n = 48.
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LBM (Table 4).
Interactions of physical activity and indices of LCn-3
intake on markers of LBM function
The number of push-ups performed was positively cor-
related with time spent in ≥moderate intensity activity
(r = 0.467; p = 0.001), total n-3 levels (r = 0.385; p =
0.012) and DHA levels (r = 0.517, p = 0.000) (Table 5).
The correlation with total n-3 levels was no longer sta-
tistically significant after adjusting for DHA. DHA main-
tained a significant association after adjusting for age,Table 3 Univariate associations between indices of erththrocyt
and quality of life (n = 43)
Total n‐3 EPA
r p-value r p-v
Weight (kg) 0.083 0.595 0.249 0.
LBM (kg) 0.093 0.554 0.156 0.
Body fat % 0.037 0.816 0.222 0.
Waist (cm) 0.123 0.431 0.280 0.
Hip (cm) 0.055 0.728 0.280 0.
CRP (mmol/L) 0.035 0.822 0.183 0.
FACT-B + 4 −0.063 0.689 0.039 0.
FACT-F −0.129 0.411 0.040 0.
LBM: Lean Body mass; CRP: C-reactive protein; EPA: eicosapentanoic acid; DHA: doc
FACT-F: Fatigue.weight, LBM and % time >mod activity (β=0.399, p =
0.001) % ≥. Mod activity remained a significant predictor
(F-Test: 8.95, p = 0.005) of the number of push-ups per-
formed in one minute after adjusting for DHA, age,
weight and LBM. There were no significant interactions
between RBC LCn-3 and time spent in any intensity of
activity for any of the regression models of physical
function (data not shown).
Discussion
This paper reports a positive relationship between LBM (ad-
justed for total weight) and physical function represented bye LCn-3 s and markers of body composition, inflammation
DHA AA/EPA
alue r p-value r p-value
107 −0.088 0.576 −0.232 0.134
319 −0.27 0.864 −0.159 0.309
153 −0.107 0.493 −0.181 0.245
069 −0.061 0.697 −0.167 0.284
069 −0.141 0.366 −0.313 0.041
241 −0.42 0.791 −0.224 0.149
804 −0.064 0.683 −0.007 0.962
797 −0.137 0.382 −0.026 0.868
osahexanoic acid; FACT-B + 4: Quality of life with breast related items;












*Regression coefficients taken from final model including: body mass, number
push‐ups performed, treadmill stage reached.
**Significance of the individual predictor within the final model.
tDenotes value reported as each variable was added into the model in the
order: body mass, stage tmill completed then no. push ups
CI = confidence interval.
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stage achieved on sub-maximal treadmill test and number
of push-ups completed. To the authors’ knowledge, this is
the first study to determine associations between physical
function and body composition in women who have com-
pleted treatment for breast cancer.
Our results agree with previous cross-sectional and
prospective cohort studies, which have shown that de-
creasing physical activity levels are associated with
greater adverse body composition change,(Irwin et al.
2003; Irwin et al. 2005) while dietary measures(Demark-
Wahnefried et al. 2001) have been less predictive of
these changes. The findings relating to the influence of
chemotherapy on LBM agree with two previous studies
(Campbell et al. 2007; Winters-Stone et al. 2009) but are
in contrast to five studies that have shown a greater de-
crease in LBM after chemotherapy (Cheney et al. 1994;
Demark-Wahnefried et al. 1997; Demark-Wahnefried
et al. 2001; Gordon et al. 2011; Kutynec et al. 1999). In
addition, Prado et al. reported that individuals with
chemotherapy toxicity had a greater risk of sarcopenia
(Prado et al. 2009). Differences in our results may be
due to the cross-sectional nature of the study. Previously
published data sets indicating LBM change after chemo-
therapy and hormonal therapies were prospective in na-
ture (Cheney et al. 1994; Demark-Wahnefried et al.
1997; Demark-Wahnefried et al. 2001; Gordon et al.
2011; Kutynec et al. 1999) and were able to see trends
over time.Table 5 Correlations between measures of physical function a
Physical function* % time>mod EPA
r p-value r p-value
Push ups 0.467 0.001 0.072 0.648
Squats 0.110 0.479 −0.338 0.029
Handgrip -0.068 0.663 0.083 0.603
Treadmill 0.224 0.138 -0.11 0.493
*Push ups: performed in one-minute; Squats: performed in one-minute; Stage of tre
% time >mod: moderate & vigorous data combined; EPA: eicosapentanoic acid; DH
**Fully adjusted model included: weight, age, % time >mod activity & LBM. CorrelaNo associations were found between erythrocyte LCn-3
and markers of body composition. Recent studies in popu-
lations during and post-chemotherapy treatment have in-
dicated a positive relationship between skeletal muscle
mass and plasma phospholipid LCn-3 content (Murphy
et al. 2010; Murphy et al. 2011), however these partici-
pants experienced significant and rapid muscle loss during
treatment. After early stage breast cancer treatment, the
rate and magnitude of muscle loss experienced is not typ-
ically as high as when compared to more advanced staged
cancers (Mcdonald et al. 2011; Murphy et al. 2010). As a
result, our results are comparable to metabolic/obese pop-
ulations undergoing similar body composition change
(Krebs et al. 2006; Noreen et al. 2010; Storlien et al. 2001).
Total body mass, push-ups performed in one-minute,
and stage completed on treadmill remained in the final
model accounting for 76% of the variation in LBM.
These results are of interest as they indicate an associ-
ation with physical function and healthier body com-
position. Specifically, the strength of association with
number of push-ups/minute as opposed to squats may
indicate the importance of whole body resistance train-
ing to maintain or achieve a higher LBM and lower fat
mass. A decrease in sports/recreational exercise has
been previously associated with an increase in adipos-
ity however, LBM change was not reported (Irwin et al.
2005). It is possible that those who performed more
push-ups due to an increase in relevant exercise train-
ing may also be more conscientious in regards to diet-
ary intake, however no association was found in this
study.
Both erythrocyte DHA and EPA content were associ-
ated with markers of physical function, surprisingly in
positive and negative directions, respectively. DHA was
strongly and independently associated with the ability to
perform push-ups, while erythrocyte EPA content was
negatively associated with squats performed. In addition,
assessing predictive models for push-up performance,
when%time ≥moderate physical activity was added to the
DHA model, a greater effect was seen. In contrast, EPA
content remained significantly negatively associated with
squats performed. Previous studies have indicated an in-
crease in muscle protein synthesis (Smith et al. 2011a;nd LCn-3 content of erythrocytes
EPA adj** DHA DHA adj.**
β p-value r pcs-value β p-value
0.212 0.118 0.517 0.000 0.399 0.001
-0.268 0.041 0.153 0.333 -0.37 0.776
-0.144 0.340 0.109 0.492 0.099 0.482
0.13 0.929 0.267 0.083 0.147 0.277
admill completed: at which 85% of estimated HRmax was reached.
A: docosahexanoic acid.
tion coefficient (β)
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et al. 2012) after supplementation of LCn-3 s was combined
with an anabolic stimulus. In advanced cancer populations,
EPA LCn-3 supplementation (often in conjunction with a
protein-rich supplement) has been associated with improve-
ments in physical function (Moses et al. 2004) and strength
(Fearon et al. 2006), while EPA and DHA LCn-3 +NSAIDs
have been shown to improve handgrip strength (Cerchietti
et al. 2007). Our results both agree and disagree with the
previous literature base with no clear reason for the oppos-
ing directions for the associations between physical function,
DHA and EPA. Further investigation into LCn-3 and phys-
ical activity interactions are required.
Our population compared favourably with larger co-
horts for body composition, (Chlebowski et al. 2002; Irwin
et al. 2005) education level, (Irwin et al. 2005) however the
exclusion of those with a diagnosed chronic disease
(T2DM or CVD) and those who could not participate in
moderate physical activity, may have led to our partici-
pants being younger and more physically active than the
general breast cancer population.
Conclusion
This is the first study to report that higher weight adjusted
LBM is associated with greater upper body strength-
endurance and aerobic fitness in women after completion
of treatment for breast cancer. Further research is re-
quired to elucidate LCn-3-exercise interactions.
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